Explore more publications!
California Health Watch
Submit Press Release

California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 8, 2025

Fujiiryoki Launches Official U.S. Online Store, Bringing Premium Japanese Wellness Direct to Consumers
October 8, 2025

Fujiiryoki Launches Official U.S. Online Store, Bringing Premium Japanese Wellness Direct to Consumers

Indeterminate EIN Presswire
Beverly Hills Gastroenterology Practice in Beverly Hills Opens New Office
October 8, 2025

Beverly Hills Gastroenterology Practice in Beverly Hills Opens New Office

Indeterminate EIN Presswire
Arthritis National Research Foundation Launches Immune Boost Capital to Accelerate Early-Stage Autoimmune Innovation
October 8, 2025

Arthritis National Research Foundation Launches Immune Boost Capital to Accelerate Early-Stage Autoimmune Innovation

Indeterminate EIN Presswire
Pluto7 Renews ML Specialization With Google Cloud, Redefining Supply Chain Planning With Agentic AI
October 8, 2025

Pluto7 Renews ML Specialization With Google Cloud, Redefining Supply Chain Planning With Agentic AI

Indeterminate EIN Presswire
hypothesis™ Becomes First Skincare Brand to Achieve Four Major Independent Certifications for Eczema Care
October 8, 2025

hypothesis™ Becomes First Skincare Brand to Achieve Four Major Independent Certifications for Eczema Care

Indeterminate EIN Presswire
Nilo Therapeutics startet mit einer Serie-A-Finanzierung in Höhe von 101 Mio. USD zur Entwicklung einer neuen Medikamentenklasse, die auf neuronale Schaltkreise bei Immunerkrankungen abzielt, und ernennt Kim Seth zum Chief Executive Officer
October 8, 2025

Nilo Therapeutics startet mit einer Serie-A-Finanzierung in Höhe von 101 Mio. USD zur Entwicklung einer neuen Medikamentenklasse, die auf neuronale Schaltkreise bei Immunerkrankungen abzielt, und ernennt Kim Seth zum Chief Executive Officer

Indeterminate GlobeNewswire
Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo
October 8, 2025

Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo

Indeterminate GlobeNewswire
Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…
October 8, 2025

Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…

Indeterminate GlobeNewswire
Nilo Therapeutics מושקה עם מימון סדרה A של 101 מיליון דולר לקידום סוג חדש של תרופות המכוונות למעגלים עצביים במחלות חיסוניות וממנה את קים סת' למנכ"ל
October 8, 2025

Nilo Therapeutics מושקה עם מימון סדרה A של 101 מיליון דולר לקידום סוג חדש של תרופות המכוונות למעגלים עצביים במחלות חיסוניות וממנה את קים סת' למנכ"ל

Indeterminate GlobeNewswire
ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…
October 8, 2025

ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…

Indeterminate GlobeNewswire
Nilo Therapeutics diluncurkan dengan pendanaan Seri A senilai 101 juta dolar AS untuk mengembangkan kelas baru obat-obatan yang menargetkan sirkuit saraf pada penyakit imun, serta menunjuk Kim Seth sebagai Direktur Utama
October 8, 2025

Nilo Therapeutics diluncurkan dengan pendanaan Seri A senilai 101 juta dolar AS untuk mengembangkan kelas baru obat-obatan yang menargetkan sirkuit saraf pada penyakit imun, serta menunjuk Kim Seth sebagai Direktur Utama

Indeterminate GlobeNewswire
Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif
October 8, 2025

Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif

Indeterminate GlobeNewswire
Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO
October 8, 2025

Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO

Indeterminate GlobeNewswire
니로 테라퓨틱스(Nilo Therapeutics), 면역질환의 신경 회로를 표적으로 하는 신약 계열 개발 추진 목표로 1억 100만 달러 규모의 시리즈 A 투자 유치에 나서며 킴 세스(Kim Seth) 박사를 CEO로 임명
October 8, 2025

니로 테라퓨틱스(Nilo Therapeutics), 면역질환의 신경 회로를 표적으로 하는 신약 계열 개발 추진 목표로 1억 100만 달러 규모의 시리즈 A 투자 유치에 나서며 킴 세스(Kim Seth) 박사를 CEO로 임명

Indeterminate GlobeNewswire
Nilo Therapeutics 啟動 1.01 億美元 A 輪融資，推進針對免疫疾病神經迴路的新型藥物研發，並任命 Kim Seth 為行政總裁
October 8, 2025

Nilo Therapeutics 啟動 1.01 億美元 A 輪融資，推進針對免疫疾病神經迴路的新型藥物研發，並任命 Kim Seth 為行政總裁

Indeterminate GlobeNewswire
Nilo Therapeutics เปิดตัวด้วยการระดมทุนรอบ Series A มูลค่าถึง 101 ล้านเหรียญสหรัฐ เพื่อพัฒนายาประเภทใหม่ที่มุ่งเป้าไปที่วงจรระบบประสาทในโรคภูมิคุ้มกัน รวมถึงแต่งตั้ง Kim Seth เป็นประธานเจ้าหน้าที่บริหา…
October 8, 2025

Nilo Therapeutics เปิดตัวด้วยการระดมทุนรอบ Series A มูลค่าถึง 101 ล้านเหรียญสหรัฐ เพื่อพัฒนายาประเภทใหม่ที่มุ่งเป้าไปที่วงจรระบบประสาทในโรคภูมิคุ้มกัน รวมถึงแต่งตั้ง Kim Seth เป็นประธานเจ้าหน้าที่บริหา…

Indeterminate GlobeNewswire
Nilo Therapeutics 启动 1.01 亿美元 A 轮融资，以推进靶向免疫疾病神经回路的新型药物研发，并任命 Kim Seth 为首席执行官
October 8, 2025

Nilo Therapeutics 启动 1.01 亿美元 A 轮融资，以推进靶向免疫疾病神经回路的新型药物研发，并任命 Kim Seth 为首席执行官

Indeterminate GlobeNewswire
Public Health Expert and Author Dr. Portia Preston announces 2 October Speaking Events featuring a Wellness Blueprint
October 8, 2025

Public Health Expert and Author Dr. Portia Preston announces 2 October Speaking Events featuring a Wellness Blueprint

Indeterminate EIN Presswire
Greenspace Herbs Unveils Physics-Driven Quantum Ayurveda at SupplySide Global
October 8, 2025

Greenspace Herbs Unveils Physics-Driven Quantum Ayurveda at SupplySide Global

Indeterminate GlobeNewswire
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
October 8, 2025

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions